Alliance Pharma Regulatory News (APH)

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Appointment of Finance Director

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, is pleased to announce the appointment of Andrew Franklin as Finance Director. Andrew will join the Company and the Board with effect from 28 September 2015.

From 2010 to 2012, Andrew was finance director and company secretary of Genzyme Therapeutics Ltd, the UK & Ireland subsidiary of Genzyme Corporation, the biotechnology company acquired by Sanofi. Prior to that, he gained 12 years' pharmaceutical experience with Wyeth in a variety of senior financial positions. Andrew joins Alliance from Panasonic Europe Ltd, where he was general manager, European tax and accounting.

He qualified as a chartered accountant with Arthur Andersen in 1992 having graduated in 1988 with a first class degree in civil engineering from University of Wales, Cardiff.

Commenting on the appointment, John Dawson, Chief Executive Officer of Alliance, said: "We welcome Andrew to Alliance as our new Finance Director. He brings considerable experience, having operated for 14 years in senior financial roles in the pharmaceutical industry. Andrew will be a strong addition to the Alliance team."

The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies. Andrew Timothy Franklin, aged 49 years, has been a director of the following companies during the five years preceding the date of this announcement:

Current directorships

None

Past directorships

Genzyme Therapeutics Limited

Bioenvision Limited

There is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

For further information:

Notes to editors:

About Alliance

Alliance, founded in 1998, is an AIM listed speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has a strong track record of acquiring the rights to established niche products and owns or licenses the rights to more than 60 pharmaceutical products and continues to explore opportunities to expand the range.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.